These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38633967)

  • 1. Clinical Biomarkers of Acute Vaso-Occlusive Sickle Cell Crisis.
    Khurana K; Mahajan S; Acharya S; Kumar S; Toshniwal S
    Cureus; 2024 Mar; 16(3):e56389. PubMed ID: 38633967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.
    Kalpatthi R; Novelli EM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):482-492. PubMed ID: 30504349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical biomarkers in sickle cell disease.
    Damanhouri GA; Jarullah J; Marouf S; Hindawi SI; Mushtaq G; Kamal MA
    Saudi J Biol Sci; 2015 Jan; 22(1):24-31. PubMed ID: 25561879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide: A potential etiological agent for vaso-occlusive crises in sickle cell disease.
    Gupta P; Kumar R
    Nitric Oxide; 2024 Mar; 144():40-46. PubMed ID: 38316197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.
    Deux JF; Audard V; Brugières P; Habibi A; Manea EM; Guillaud-Danis C; Godeau B; Galactéros F; Stehlé T; Lang P; Grimbert P; Audureau E; Rahmouni A; Bartolucci P
    Am J Kidney Dis; 2017 Jan; 69(1):51-59. PubMed ID: 27663041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity.
    Li W; Pucka AQ; Debats C; Reyes BA; Syed F; O'Brien ARW; Mehta R; Manchanda N; Jacob SA; Hardesty BM; Greist A; Harte SE; Harris RE; Yu Q; Wang Y
    Front Immunol; 2024; 15():1288187. PubMed ID: 38361924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism.
    Hamali HA
    Hemoglobin; 2023 Nov; 47(6):205-214. PubMed ID: 38189099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
    Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL
    Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular pathophysiology of sickle cell disease.
    Connes P; Renoux C; Joly P; Nader E
    Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease.
    Al Najjar S; Adam S; Ahmed N; Qari M
    Ann Hematol; 2017 Jan; 96(1):141-146. PubMed ID: 27686084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.
    Shilo NR; Morris CR
    Expert Rev Hematol; 2017 Oct; 10(10):875-890. PubMed ID: 28817980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of thrombin generation assay to predict vaso-occlusive crisis in adulthood with sickle cell disease.
    Feugray G; Kasonga F; Grall M; Dumesnil C; Benhamou Y; Brunel V; Le Cam Duchez V; Lahary A; Billoir P
    Front Cardiovasc Med; 2022; 9():883812. PubMed ID: 36277754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
    Ferreira de Matos C; Comont T; Castex MP; Lafaurie M; Walter O; Moulis G; Dion J; Cougoul P
    Expert Rev Hematol; 2022 Dec; 15(12):1045-1054. PubMed ID: 36412212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis.
    Antwi-Boasiako C; Frimpong E; Ababio GK; Dzudzor B; Ekem I; Gyan B; Sodzi-Tettey NA; Antwi DA
    Ghana Med J; 2015 Jun; 49(2):102-6. PubMed ID: 26339094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.